Germany’s cannabis debate turns back to child protection, courts and local controls

Bavaria becomes a test case for protecting cannabis clubs from local barriers

The case also lands in a political climate where the federal cannabis reform remains contested. That makes the Bavarian lawsuit more than a local administrative quarrel: it is one of the places where Germany’s broader struggle over implementation, public order and protection of young people is being fought in practice.

Teen exposure remains the central public-health concern

While the Bavarian case is about regulation, the public-health debate is about consequences. Several reports in early 2026 pointed in the same direction: adolescents who use cannabis are being linked to higher later risks of serious mental health problems, renewing attention on how minors are shielded from psychoactive substances. A February 25 report on teen cannabis use and mental health said new research connected adolescent use with increased risk for serious mental health conditions. A separate Kaiser Permanente summary said teens who report cannabis use are more likely to later receive serious mental health diagnoses.

The warnings did not come from one source alone. NPR-reported research in February said a large study found teen cannabis use was associated with a higher later risk of serious mental health problems, while an AAP News item noted that teen substance use remains below pre-pandemic levels overall, even as intoxicating hemp products such as delta-8-THC continue to appear in adolescent use patterns. Together, those reports suggest a policy environment in which overall use may fluctuate, but the concern about early exposure remains firmly in place.

• Adolescent use is being tied to higher later risk of serious mental health conditions.
• Overall teen substance use is still reported below pre-pandemic levels.
• Intoxicating hemp products such as delta-8-THC remain part of the youth-use picture.
• Public-health messaging is increasingly about psychoactive exposure in general, not cannabis alone.

The substance category is widening too. A German report from MDR said restrictions on nitrous oxide and knock-out drugs took effect in April 2026, with the story explicitly stressing the health risks for minors. That places cannabis alongside other psychoactive substances in a broader prevention debate: the question is not just whether one drug is legal, but how states keep adolescents away from a range of intoxicating products.

Europe’s drug market is getting more complex, and younger people are in the frame

The concern over minors is not limited to Germany. On June 9, 2026, Euronews reported that the EU drug agency warned about stronger cannabis, potent opioids and new substances raising health risks across Europe. The same day, reporting from Greece said cannabis use among teenagers had reached a 25-year high, a reminder that youth exposure is not a theoretical issue. Across the Atlantic, MPR News reported that Minnesota teen cannabis use continued to decline in May 2026, although schools still saw cases of anxiety and hallucination linked to drug use.

Taken together, these reports point to a policy tension that runs through every youth-protection debate. Even where overall use levels are flat or falling, the potency, availability and diversification of intoxicating substances can still change the risk profile for minors. That is why the language of protection now stretches beyond conventional cannabis policy into wider prevention strategies, school health and mental-health screening.

Germany’s own internal debate over legalization now sits inside that wider context. The more officials and courts argue about the structure of the adult market, the more clearly the youth-protection question remains the baseline against which reforms are judged.

Germany’s legalization dispute keeps circling back to access and safeguards

The adult-use reform that came into force in 2024 did not settle the political argument. AP reported that Germany legalized possession of up to 25 grams for adults and allowed home growing and nonprofit cannabis clubs under the new law, while another AP report said lawmakers approved the plan to decriminalize limited possession and permit clubs for recreational use. Yet the political reaction has remained divided. DW’s account of the first year of legalized cannabis said the country was still debating youth protection and access to legal supply, and later reporting noted that conservatives called for a rethink after a two-year review.

That argument has concrete institutional consequences. A federal report cited in government debate said the illegal market had shrunk, but medical prescriptions had risen unusually. In parallel, a separate DW report said the law remained bureaucratic and unclear for regulators, particularly in the club system. The result is a policy landscape in which the same reform is being defended as a way to better control access, and criticised as unfinished or too hard to administer.

The legal and political back-and-forth is important for child protection because implementation determines visibility, control and enforcement. When the rules are unclear, it becomes harder to know whether the system is actually creating safer, more bounded access for adults — or simply shifting demand into a grey zone that is less easy to supervise.

Medical cannabis keeps expanding, but the safeguards around it are still contested

The youth-protection debate also overlaps with Germany’s medical cannabis market, which has grown rapidly since reclassification. High Times reported that prescriptions rose by more than 3,300% by late 2025 after cannabis was removed from the narcotics law and reclassified as a non-narcotic medication. GreenState likewise said prescriptions climbed by over 3,300% versus March 2024, driven by telemedicine and easier access. Prohibition Partners described Germany as Europe’s largest medical cannabis market and pointed to telemedicine-led private-pay access as the main growth driver after MedCanG.

At the same time, the market’s expansion has not erased professional caution. HealthPolicy Online reported that only about one in ten German general practitioners would prescribe medical cannabis. A legal news item on the Federal Court of Justice said the court reaffirmed that advertising prescription-only medical cannabis to consumers remains prohibited, allowing information but not promotion. That kind of boundary matters in a report about minors because it shows how tightly Germany is still trying to separate regulated medical access from general consumer signalling.

Import dependence reinforces the point. Ziel said Germany imported over 72 tonnes of medical cannabis in 2024, underlining how much of the prescription market still rests on external supply chains. A separate market report from Hanf Magazin described Germany as central to the global medical cannabis market, while Cansativa expected the sector to keep stabilizing and professionalizing in 2026. The market may be maturing, but the rules around communication, prescribing and access remain guarded.

What the next phase may look like for clubs, pilots and state enforcement

Beyond the courtroom and the medical market, the next phase of Germany’s cannabis policy is still unresolved. Reporting from Pharmazeutische Zeitung said Hendrik Streeck is pushing for cannabis model projects, reviving discussion of regional retail trial plans. Other specialised reports said Germany’s second legalization pillar remains pending, with first tender calls for regional model projects expected only in the second half of 2026 and compliance requirements still uncertain amid diverging federal and state positions.

That uncertainty is central to the question of protecting minors. Pilot projects, if they come, will be tested not only on market design but on how well they can separate adult access from youth exposure, local disorder and legal ambiguity. For now, however, the state-by-state picture remains fragmented: one part of the system is being litigated in Bavaria, another is being discussed as a regional experiment, and the public-health warnings continue to arrive from outside the legal reform track altogether.

The legalisation debate may be about adult access, but the public-health standard remains the same: minors should not be left to absorb the risks of an expanding psychoactive market.